Conferences - Results from #20

Viewing 21-40 of 11487 articles

SNMMI 2024: Combination Treatment of Prostate Cancer Using Pembrolizumab with PSMA Based Radioligands

AMA 2024: Championing Change: The AMA's Vital Advocacy Initiatives for Physicians

SNMMI 2024: Safety, Tolerability, and Dosimetry of TLX591 with Best Standard of Care in Patients with PSMA-Expressing Metastatic Castration Resistant Prostate Cancer: ProstACT SELECT Preliminary Results

SNMMI 2024: PSMA PET in Patients with Prostate Cancer – Gained Insights from Eight Years of Reimbursable Imaging

SNMMI 2024: Saul Hertz’s Theranostic Dream is Shaping the Future of Cancer Care: Bridging Evidence-Based Medicine and Precision Oncology

SNMMI 2024: PSMA Radioligand Therapy in Patients with Prostate Cancer: Technical Considerations for Diagnostic, Quantitative, and Dosimetric Imaging

SNMMI 2024: Novel Approaches of Combination PSMA-Based Radiopharmaceutical Treatments for Prostate Cancer

SNMMI 2024: Analysis of the Prospective ProsTIC Registry

SNMMI 2024: 225Ac-PSMA / 177Lu-PSMA Tandem Therapy for Metastatic Castration-Resistant Prostate Cancer – A Prospective Phase 3 Randomized Study from Azerbaijan

SNMMI 2024: Efficacy and Toxicity of 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer in a Real-World Setting: Results from the U.S. Expanded Access Program and Comparison with Phase 3 VISION Data

SNMMI 2024: Effect of Bone Marrow Disease on Hematologic Toxicity and PSA Response to 177Lu-PSMA-617 Therapy

SNMMI 2024: Lu-177-PSMA-I&T Treatment in Metastatic Castration Resistant Prostate Cancer: First Experience in Thailand

SNMMI 2024: PSMA RLT: Is Earlier Better?

SNMMI 2024: Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer (PSMAfore)

SNMMI 2024: Influence of Androgen Receptor Signaling Inhibitors on Absorbed Doses in mCRPC Patients Undergoing 177Lu-PSMA-617 Therapy: First Dosimetry Results

SNMMI 2024: PSMA RLT: Does One Size Fit All?

SNMMI 2024: Primary Lesion Ga-68 PSMA-11 Total Lesion Activity Is a Highly Sensitive Predictor with High Negative Predictive Value of Advanced Stage in Initial Staging of Patients with Moderate to High-Risk Prostate Cancer

SNMMI 2024: 68Ga-PSMA-11 PET/CT for Baseline Staging of High-Risk Prostate Cancer: Associations Between Clinical Risk Factors, Metastases and Imaging Parameters

SNMMI 2024: 18F-PSMA-1007 PET /CT in Evaluation of Atypical Patterns of Spread in ISUP Grade Group 5 Prostate Cancer and Correlation with NKX3.1 Immunohistochemistry

SNMMI 2024: Percutaneous Trans-Gluteal Ga-68 PSMA PET/CT Guided Prostate Biopsy in Men with Equivocal Multiparametric MRI Findings (PIRADS≤3 Prostatic Lesion)

1
2
3
4
5
6
7
8
9
10